BACKGROUND: This study investigates pharmacogenetic risk factors for bone mineral (apparent) density (BM(A)D) and body composition in pediatric acute lymphoblastic leukemia DESIGN AND METHODS: We determined the influence of SNPs in 4 genes (vitamin-D receptor (VDR: BsmI/ApaI/TaqI and Cdx-2/GATA), collagen type I alpha 1 (SpI), estrogen receptor 1 (ESR1: PvuII/XbaI), glucocorticoid receptor (BclI)) on body composition, BM(A)D and fracture risk during dexamethasone-based pediatric acute lymphoblastic leukemia treatment. Body composition and BMD were measured repeatedly during and after treatment using dual energy X-ray absorptiometry. RESULTS: Non-carriers of VDR 5'-end (Cdx-2/GATA) haplotype 3 revealed a significant larger fat gain than carriers (Delta%fat: non-carriers: +1.76SDS, carriers: +0.77SDS, P<0.001). At diagnosis and during therapy, lumbar spine BMD was significantly higher in non-carriers of VDR 5'-end (Cdx-2/GATA) haplotype 3 than in carriers. The other SNPs did not influence BMD or fracture risk during/after treatment. The year after treatment completion, lean body mass increased in non-carriers of ESR1 (PvuII/XbaI) haplotype 3 and decreased in carriers (Delta lean body mass: non-carriers:+0.28SDS, carriers: -0.55SDS, P<0.01). CONCLUSIONS: Only VDR 5'-end (Cdx-2/GATA) haplotype 3 was identified as protective factor against excessive fat gain and as a risk factor for lower lumbar spine BMD during treatment. Carrying ESR1 (PvuII/XbaI) haplotype 3 negatively influenced recovery of lean body mass after pediatric acute lymphoblastic leukemia treatment.
BACKGROUND: This study investigates pharmacogenetic risk factors for bone mineral (apparent) density (BM(A)D) and body composition in pediatric acute lymphoblastic leukemia DESIGN AND METHODS: We determined the influence of SNPs in 4 genes (vitamin-D receptor (VDR: BsmI/ApaI/TaqI and Cdx-2/GATA), collagen type I alpha 1 (SpI), estrogen receptor 1 (ESR1: PvuII/XbaI), glucocorticoid receptor (BclI)) on body composition, BM(A)D and fracture risk during dexamethasone-based pediatric acute lymphoblastic leukemia treatment. Body composition and BMD were measured repeatedly during and after treatment using dual energy X-ray absorptiometry. RESULTS: Non-carriers of VDR 5'-end (Cdx-2/GATA) haplotype 3 revealed a significant larger fat gain than carriers (Delta%fat: non-carriers: +1.76SDS, carriers: +0.77SDS, P<0.001). At diagnosis and during therapy, lumbar spine BMD was significantly higher in non-carriers of VDR 5'-end (Cdx-2/GATA) haplotype 3 than in carriers. The other SNPs did not influence BMD or fracture risk during/after treatment. The year after treatment completion, lean body mass increased in non-carriers of ESR1 (PvuII/XbaI) haplotype 3 and decreased in carriers (Delta lean body mass: non-carriers:+0.28SDS, carriers: -0.55SDS, P<0.01). CONCLUSIONS: Only VDR 5'-end (Cdx-2/GATA) haplotype 3 was identified as protective factor against excessive fat gain and as a risk factor for lower lumbar spine BMD during treatment. Carrying ESR1 (PvuII/XbaI) haplotype 3 negatively influenced recovery of lean body mass after pediatric acute lymphoblastic leukemia treatment.
Authors: A M Fredriks; S van Buuren; R J Burgmeijer; J F Meulmeester; R J Beuker; E Brugman; M J Roede; S P Verloove-Vanhorick; J M Wit Journal: Pediatr Res Date: 2000-03 Impact factor: 3.756
Authors: A M Boot; M M van den Heuvel-Eibrink; K Hählen; E P Krenning; S M de Muinck Keizer-Schrama Journal: Eur J Cancer Date: 1999-11 Impact factor: 9.162
Authors: V Mann; E E Hobson; B Li; T L Stewart; S F Grant; S P Robins; R M Aspden; S H Ralston Journal: J Clin Invest Date: 2001-04 Impact factor: 14.808
Authors: I M van der Sluis; S M P F de Muinck Keizer-Schrama; E P Krenning; H A P Pols; A G Uitterlinden Journal: Calcif Tissue Int Date: 2003-07-24 Impact factor: 4.333
Authors: Elisabeth F C van Rossum; Jan W Koper; Annewieke W van den Beld; André G Uitterlinden; Pascal Arp; Wietske Ester; Joop A M J L Janssen; Albert O Brinkmann; Frank H de Jong; Diederick E Grobbee; Huibert A P Pols; Steven W J Lamberts Journal: Clin Endocrinol (Oxf) Date: 2003-11 Impact factor: 3.478
Authors: S C Kaste; A Qi; K Smith; H Surprise; E Lovorn; J Boyett; R J Ferry; M V Relling; S A Shurtleff; C H Pui; L Carbone; M M Hudson; K K Ness Journal: Pediatr Blood Cancer Date: 2014-01-07 Impact factor: 3.167
Authors: Hiroto Inaba; Xueyuan Cao; Alice Q Han; John C Panetta; Kirsten K Ness; Monika L Metzger; Jeffrey E Rubnitz; Raul C Ribeiro; John T Sandlund; Sima Jeha; Cheng Cheng; Ching-Hon Pui; Mary V Relling; Sue C Kaste Journal: Cancer Date: 2017-12-19 Impact factor: 6.860
Authors: Marissa A H den Hoed; Saskia M F Pluijm; Mariël L te Winkel; Hester A de Groot-Kruseman; Martha Fiocco; Peter Hoogerbrugge; Jan A Leeuw; Marrie C A Bruin; Inge M van der Sluis; Dorien Bresters; Maarten H Lequin; Jan C Roos; Anjo J P Veerman; Rob Pieters; Marry M van den Heuvel-Eibrink Journal: Haematologica Date: 2015-09-24 Impact factor: 9.941
Authors: Adriana Aparecida Siviero-Miachon; Angela Maria Spinola-Castro; Maria Lucia de Martino Lee; Antonio Ramos Calixto; Bruno Geloneze; Marise Lazaretti-Castro; Gil Guerra-Junior Journal: J Bone Miner Metab Date: 2015-12-11 Impact factor: 2.626
Authors: Audrey H Poon; Li Gong; Charlotte Brasch-Andersen; Augusto A Litonjua; Benjamin A Raby; Qutayba Hamid; Catherine Laprise; Scott T Weiss; Russ B Altman; Teri E Klein Journal: Pharmacogenet Genomics Date: 2012-10 Impact factor: 2.089
Authors: Jenneke E van Atteveld; Saskia M F Pluijm; Kirsten K Ness; Melissa M Hudson; Wassim Chemaitilly; Sue C Kaste; Leslie L Robison; Sebastian J C M M Neggers; Yutaka Yasui; Marry M van den Heuvel-Eibrink; Carmen L Wilson Journal: J Clin Oncol Date: 2019-05-31 Impact factor: 50.717
Authors: Jenneke E van Atteveld; Demi Tc de Winter; Rob Pieters; Sebastian Jcmm Neggers; Marry M van den Heuvel-Eibrink Journal: Fac Rev Date: 2021-06-23